Piper Sandler analyst Allison Bratzel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $87 and keeps an Overweight rating on the shares following Q4 reporting. Total revenue guidance of $825M-$850M came in lower than consensus expectations of $931M. However, this was in part driven by conservatism on review timing for olezarsen in sHTG, and given the news that FDA accepted the filing with Priority Review and a PDUFA of June 30, Piper expects an upward revision of guidance when Ionis reports Q1 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals announces olezarsen sNDA accepted for FDA priority review
- Ionis Pharmaceuticals price target raised to $77 from $73 at Stifel
- Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum
- Ionis Pharmaceuticals: Accelerating Commercial Momentum, Conservative Guidance, and Late-Stage Pipeline Catalysts Underpin Buy Rating
- Ionis Pharmaceuticals: Strong 4Q25 Beat and Catalyst-Rich 2026 Underpin Raised Buy Rating and $103 Target